JPS6124370B2 - - Google Patents
Info
- Publication number
- JPS6124370B2 JPS6124370B2 JP53126751A JP12675178A JPS6124370B2 JP S6124370 B2 JPS6124370 B2 JP S6124370B2 JP 53126751 A JP53126751 A JP 53126751A JP 12675178 A JP12675178 A JP 12675178A JP S6124370 B2 JPS6124370 B2 JP S6124370B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- coronavirus
- diarrhea
- bovine
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000700605 Viruses Species 0.000 claims description 106
- 241000283690 Bos taurus Species 0.000 claims description 85
- 206010012735 Diarrhoea Diseases 0.000 claims description 53
- 229960005486 vaccine Drugs 0.000 claims description 40
- 244000309466 calf Species 0.000 claims description 39
- 230000002238 attenuated effect Effects 0.000 claims description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 5
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000011126 aluminium potassium sulphate Nutrition 0.000 claims description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 2
- 229940050271 potassium alum Drugs 0.000 claims description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims description 2
- 229960000380 propiolactone Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 33
- 238000000034 method Methods 0.000 description 28
- 210000003292 kidney cell Anatomy 0.000 description 17
- 230000001605 fetal effect Effects 0.000 description 15
- 230000000741 diarrhetic effect Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000006143 cell culture medium Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 241000711573 Coronaviridae Species 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 6
- 230000000415 inactivating effect Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 241000702263 Reovirus sp. Species 0.000 description 4
- 229940001442 combination vaccine Drugs 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000702244 Orthoreovirus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 1
- 241000711443 Bovine coronavirus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000068291 Galium asprellum Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000251 trophoblastic cell Anatomy 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30217972A | 1972-10-30 | 1972-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5531058A JPS5531058A (en) | 1980-03-05 |
JPS6124370B2 true JPS6124370B2 (US20100170793A1-20100708-C00006.png) | 1986-06-10 |
Family
ID=23166611
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP48122156A Expired JPS5817169B2 (ja) | 1972-10-30 | 1973-10-30 | シンセイコウシゲリワクチンノ セイホウ |
JP12675178A Granted JPS5531058A (en) | 1972-10-30 | 1978-10-13 | Manufacture of newly born calf diarrhea vaccine |
JP56215939A Granted JPS57131726A (en) | 1972-10-30 | 1981-12-28 | Composite diarrhes vaccine for new born calf |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP48122156A Expired JPS5817169B2 (ja) | 1972-10-30 | 1973-10-30 | シンセイコウシゲリワクチンノ セイホウ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56215939A Granted JPS57131726A (en) | 1972-10-30 | 1981-12-28 | Composite diarrhes vaccine for new born calf |
Country Status (17)
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6027007U (ja) * | 1983-07-30 | 1985-02-23 | 株式会社 協立双葉自動機 | 容器回転速度調整装置付きラベリングマシン |
JPH0518338Y2 (US20100170793A1-20100708-C00006.png) * | 1985-12-27 | 1993-05-17 | ||
ZA872532B (en) * | 1986-04-21 | 1987-11-25 | Akzo Nv | Combined vaccine |
GB8818415D0 (en) * | 1988-08-03 | 1988-09-07 | Animal Health Inst | Vaccine |
US6291228B1 (en) | 1988-08-03 | 2001-09-18 | Vericore Limited | Vaccine |
JPH08786B2 (ja) * | 1993-02-25 | 1996-01-10 | 株式会社微生物化学研究所 | 牛コロナウイルス感染症ワクチン |
CN108350437B (zh) | 2015-11-06 | 2021-10-15 | 旭化成医疗株式会社 | 高感染滴度且高纯度的细小病毒的产生方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE759425A (fr) * | 1969-11-28 | 1971-05-25 | Mebus Charles A | Vaccins contre la diarrhee du veau, leur preparation et emploi |
US3629413A (en) * | 1970-02-04 | 1971-12-21 | Univ Southern Illinois | Polyvalent bovine vaccines and methods of making and using same |
-
1973
- 1973-10-16 SE SE7314001A patent/SE419500B/xx unknown
- 1973-10-17 NL NL7314293A patent/NL7314293A/xx unknown
- 1973-10-23 AR AR250655A patent/AR200155A1/es active
- 1973-10-23 GB GB4925373A patent/GB1401565A/en not_active Expired
- 1973-10-24 AU AU61774/73A patent/AU476160B2/en not_active Expired
- 1973-10-26 BE BE137108A patent/BE806568A/xx not_active IP Right Cessation
- 1973-10-26 IE IE1925/73A patent/IE38423B1/xx unknown
- 1973-10-26 ES ES419996A patent/ES419996A1/es not_active Expired
- 1973-10-26 DD DD174314A patent/DD110517A5/xx unknown
- 1973-10-29 CA CA184,534A patent/CA1019675A/en not_active Expired
- 1973-10-29 CH CH1521373A patent/CH596315A5/xx not_active IP Right Cessation
- 1973-10-29 ZA ZA738329A patent/ZA738329B/xx unknown
- 1973-10-29 FI FI733344A patent/FI52740C/fi active
- 1973-10-30 HU HU73BO1469A patent/HU168486B/hu unknown
- 1973-10-30 JP JP48122156A patent/JPS5817169B2/ja not_active Expired
- 1973-10-30 DE DE2354324A patent/DE2354324C2/de not_active Expired
- 1973-10-30 FR FR7338701A patent/FR2204405B1/fr not_active Expired
-
1978
- 1978-10-13 JP JP12675178A patent/JPS5531058A/ja active Granted
-
1981
- 1981-12-28 JP JP56215939A patent/JPS57131726A/ja active Granted
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3919413A (en) | Vaccine for neonatal calf diarrhea | |
Chumakov et al. | Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria | |
US4567042A (en) | Inactivated canine coronavirus vaccine | |
AU703084B2 (en) | Low pathogenicity prrs live virus vaccines and methods of preparation thereof | |
US4645665A (en) | Live infectious bronchitis vaccine for poultry | |
US3914408A (en) | Vaccine for neonatal calf diarrhea | |
ITTO940713A1 (it) | Vaccino per la prevenzione della sindrome riproduttiva e respiratoria porcina. | |
JP2655876B2 (ja) | イヌ科コロナウイルスワクチン | |
DK162421B (da) | Hundeparvovirus-vaccine, fremgangsmaade til fremstilling heraf og virusstamme til brug i vaccinen | |
Letchworth 3rd et al. | Passive protection of mice and sheep against bluetongue virus by a neutralizing monoclonal antibody | |
US3873422A (en) | Vaccine for neonatal calf diarrhea | |
Howie et al. | Identification of a strain of infectious bursal disease virus isolated from mosquitoes. | |
CA1184115A (en) | Infectious bronchitis vaccines for poultry and process for the preparation of such vaccines | |
JPS6124370B2 (US20100170793A1-20100708-C00006.png) | ||
AU705186B2 (en) | Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection | |
RU2378014C2 (ru) | Ассоциированная вакцина против парагриппа-3, инфекционного ринотрахеита и коронавирусной инфекции крупного рогатого скота эмульсионная инактивированная | |
JPS6330288B2 (US20100170793A1-20100708-C00006.png) | ||
RU2699671C1 (ru) | Вакцина для ранней защиты против ящура типа О инактивированная эмульсионная | |
US3919412A (en) | Vaccine for neonatal calf diarrhea | |
US3105011A (en) | Antigens and process of producing same | |
Mayr et al. | Electron optical and buoyant density studies of hog cholera virus | |
Kulkarni et al. | Assessment of the immune response to duck plague vaccinations | |
JPH07504897A (ja) | ネコ感染性腹膜炎ワクチンおよび調製方法 | |
JP4373916B2 (ja) | ニワトリ2型アストロウイルス | |
KR100934687B1 (ko) | 고양이 칼리시바이러스 질병에 대한 불활성화 백신 |